Alota, Jhaydeil A.

HRN: 23-12-81  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/02/2023
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
06/02/2023
06/08/2023
PO
7.5ml
Q12
UTI
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Urinary Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: